Crenolanib

Drug Profile

Crenolanib

Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besilate; Crenolanib besylate; IND 112201

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer AROG Pharmaceuticals; University of Ulm
  • Class Antineoplastics; Benzimidazoles; Piperidines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Acute myeloid leukaemia; Soft tissue sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
  • Phase II Glioblastoma; Non-small cell lung cancer
  • Phase I Cancer; Glioma
  • Preclinical Systemic mastocytosis
  • Research Soft tissue sarcoma

Most Recent Events

  • 06 Dec 2016 Interim results from a phase I/II trial in Acute myeloid leukaemia reported at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 03 Dec 2016 Efficacy and adverse events data from a phase II trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 21 Nov 2016 Early research in Soft tissue sarcoma in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top